Catalent
CTLT
#1737
Rank
A$17.34 B
Marketcap
A$95.57
Share price
0.00%
Change (1 day)
10.49%
Change (1 year)
Catalent is an American pharmaceutical contract research and development company.

Catalent (CTLT) - Total debt

Total debt on the balance sheet as of September 2024 : A$7.44 Billion

According to Catalent's latest financial reports the company's total debt is A$7.44 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Catalent - Total debt on balance sheet (from 2013 to 2024)

Total debt by year

Year Total debt Change
2023-06-30A$7.29 B19.31%
2022-06-30A$6.11 B40.71%
2021-06-30A$4.34 B-1.15%
2020-06-30A$4.39 B4.29%
2019-06-30A$4.21 B14.63%
2018-06-30A$3.67 B35.7%
2017-06-30A$2.70 B8.45%
2016-06-30A$2.49 B2.18%
2015-06-30A$2.44 B-14.96%
2014-06-30A$2.87 B-2.5%
2013-06-30A$2.94 B12.53%
2012-06-30A$2.62 B

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Supernus Pharmaceuticals
SUPN
A$63.55 M-99.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Aerie Pharmaceuticals
AERI
A$0.50 B-93.19%๐Ÿ‡บ๐Ÿ‡ธ USA
Jazz Pharmaceuticals
JAZZ
A$8.17 B 9.73%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
Intercept Pharmaceuticals
ICPT
A$0.33 B-95.47%๐Ÿ‡บ๐Ÿ‡ธ USA